Novocure Stock Performance
| NVCR Stock | USD 12.33 0.60 4.64% |
The company secures a Beta (Market Risk) of 1.74, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novocure will likely underperform. Novocure right now secures a risk of 3.4%. Please verify Novocure downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Novocure will be following its current price movements.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Novocure has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Novocure is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 242.6 M | |
| Total Cashflows From Investing Activities | -140.2 M |
Novocure Relative Risk vs. Return Landscape
If you would invest 1,269 in Novocure on September 19, 2025 and sell it today you would lose (36.00) from holding Novocure or give up 2.84% of portfolio value over 90 days. Novocure is currently generating 0.0109% in daily expected returns and assumes 3.3985% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Novocure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Novocure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novocure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novocure, and traders can use it to determine the average amount a Novocure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0032
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVCR |
Based on monthly moving average Novocure is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novocure by adding Novocure to a well-diversified portfolio.
Novocure Fundamentals Growth
Novocure Stock prices reflect investors' perceptions of the future prospects and financial health of Novocure, and Novocure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novocure Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.083 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 1.21 B | ||||
| Shares Outstanding | 111.98 M | ||||
| Price To Earning | 721.15 X | ||||
| Price To Book | 4.24 X | ||||
| Price To Sales | 2.25 X | ||||
| Revenue | 605.22 M | ||||
| EBITDA | (109.58 M) | ||||
| Cash And Equivalents | 948.52 M | ||||
| Cash Per Share | 9.06 X | ||||
| Total Debt | 683.35 M | ||||
| Debt To Equity | 1.31 % | ||||
| Book Value Per Share | 3.05 X | ||||
| Cash Flow From Operations | (26.37 M) | ||||
| Earnings Per Share | (1.61) X | ||||
| Total Asset | 1.24 B | ||||
| Retained Earnings | (1.15 B) | ||||
| Current Asset | 293.9 M | ||||
| Current Liabilities | 28.63 M | ||||
About Novocure Performance
Assessing Novocure's fundamental ratios provides investors with valuable insights into Novocure's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Novocure is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. NovoCure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.Things to note about Novocure performance evaluation
Checking the ongoing alerts about Novocure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novocure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novocure had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 605.22 M. Net Loss for the year was (168.63 M) with profit before overhead, payroll, taxes, and interest of 485.09 M. | |
| Novocure currently holds about 948.52 M in cash with (26.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.06. | |
| Novocure has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors |
- Analyzing Novocure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novocure's stock is overvalued or undervalued compared to its peers.
- Examining Novocure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novocure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novocure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novocure's stock. These opinions can provide insight into Novocure's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.